NewsNews

an hour of the quake people beganinspecting the buildings."

Although preparation and buildingdesigns helped minimize damage,people still felt fortunate that the cir-cumstances did not turn out worse. Asfor the separated Health Sciences build-ing, "Maybe the next big one will push itback together," Fisher said.

— Troy Parkins

Awards,Appointments,Announcements

Peter A. Jones, Ph.D., has beennamed director of the University ofSouthern California/Norris Compre-hensive;Cancer Center, Los Angeles.Jones has been interim director sincelast February. He succeeds BrianHenderson, M.D., now president ofthe Salk Institute.

Jones is a professor of biochem-istry and molecular biology and urol-ogy at the University of SouthernCalifornia School of Medicine. TheUSC/Norris Comprehensive CancerCenter is also affiliated with theUniversity of Southern CaliforniaSchool of Medicine.

Bowman Appointed at NeoRx

NeoRx Corporation elected JackL. Bowman to its board of directorsin January. Bowman had recentlyretired as company group chairman atJohnson & Johnson Company. Priorto his work at Johnson & Johnson,Bowman was executive vice president

of American Cyanamid Corporationand president of its Lederle Labora-tories Division.

NeoRx Corporation develops mono-clonal antibody-based products thathelp diagnose and treat some types ofcancer.

Borch, Weinstein Named

Terrapin Technologies, Inc., hasnamed Richard F. Borch, M.D.,Ph.D., and Harel Weinstein, D.Sc., toits Science Advisory Board. Borch isdirector of the University of RochesterCancer Center, New York. Weinstein isprofessor and chairman of the depart-ment of physiology and biophysics atMount Sinai School of Medicine,New York.

Terrapin Technologies is a biophar-maceutical company located in SouthSan Francisco, Calif. The two recentappointments brings the number ofmembers on Terrapin's Science AdvisoryBoard to 11.

Dr. Peter A. Jones

Chiron Changes Name

Chiron Corporation announced inJanuary it had changed the names of itsconsolidated oncology businesses,Cetus Oncology and EuroCetus, to theshared name of Chiron Therapeutics.This name change will be implementedin both the United States and Europe.

Located in Emeryville, Calif., Chironis a health care business with interests indiagnostics, vaccines, and therapeutics.

Chiron Therapeutics will be col-laborating with other companies todevelop new chemotherapeutics. Theyare also instituting a series of 1-800telephone services for customers andprofessionals to call for product infor-mation, educational materials, andinformation about patient support.

Errata

In the Jan. 5, 1994, issue of theNews, Gary Chase, Ph.D., a professor inthe Department of Mental Hygiene atthe Johns Hopkins University, Balti-more, was misidentified in the article,"RAC Splits Approval on Two GeneTherapy Protocols." Chase, a memberof the National Institutes of HealthRecombinant DNA Advisory Commit-tee, was identified as a professor in theDepartment of Dental Hygiene. TheNews apologizes for the typographicalerror.

In the Feb. 2, 1994, issue of theNews, the article, "Researchers TestTIMP-2 as Potential Tumor Terminator,"BB94, a synthetic metalloproteinase in-hibitor, is referred to as both a metallo-proteinase and a metalloproteinaseinhibitor. The latter is correct.

(Items in "Awards, Appointments,Announcements" are compiled fromnotices received by the News section.Not all notices are used; all those usedare edited.)

264 NEWS Journal of the National Cancer Institute, Vol. 86, No. 4, February 16, 1994

Dow

nloaded from https://academ

ic.oup.com/jnci/article/86/4/264/894208 by guest on 30 N

ovember 2021